News & Updates
Filter by Specialty:
Fewer CV events after COVID-19 vaccine-related myocarditis
In a nationwide French cohort study, myocarditis attributed to COVID-19 mRNA vaccination causes fewer cardiovascular (CV) events at 18 months of follow-up than that attributed to SARS-CoV-2 infection or myocarditis of conventional aetiologies.
Fewer CV events after COVID-19 vaccine-related myocarditis
13 Sep 2024
Tenecteplase at 4.5–24 hours without thrombectomy feasible for ischaemic stroke
The use of tenecteplase in the extended time window of 4.5–24 hours improves functional outcomes in patients with ischaemic stroke when endovascular thrombectomy (EVT) is not immediately available, findings from the phase III TRACE-III* trial suggest.
Tenecteplase at 4.5–24 hours without thrombectomy feasible for ischaemic stroke
11 Sep 2024
Hydroxychloroquine protects SLE patients against CV events
Among patients with systemic lupus erythematosus (SLE), those who use of hydroxychloroquine are less likely to experience cardiovascular events, as reported in a study.
Hydroxychloroquine protects SLE patients against CV events
11 Sep 2024
Four-drug pill beats three separate meds in difficult-to-treat hypertension
For individuals with difficult-to-treat hypertension who are struggling with three separate medications, a single pill that combines four blood pressure (BP)-lowering drugs may help with BP control, as shown in the phase III QUADRO trial.
Four-drug pill beats three separate meds in difficult-to-treat hypertension
07 Sep 2024
Paediatric T2DM: Prevalence of microalbuminuria doubles within 2 years of diagnosis
Data from the Hong Kong Childhood Diabetes Registry (HKCDR) show that 2 years after diagnosis of paediatric type 2 diabetes mellitus (T2DM), approximately 20–65 percent of patients have ≥1 of the following: microalbuminuria (MA), suboptimal glycaemic control, hypertension, or dyslipidaemia.